Please ensure Javascript is enabled for purposes of website accessibility

Is Vaccine Latecomer Inovio Making a Comeback?

By Adria Cimino – Sep 29, 2021 at 6:00AM

Key Points

  • Three countries have agreed to participate in the late-stage trial of Inovio’s coronavirus vaccine candidate.
  • Inovio aims to focus on countries where need for coronavirus vaccines remains high.
  • Inovio shares have dropped more than 70% from a high point last year.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Its new plan for phase 3 trials is advancing.

Inovio Pharmacauticals (INO 1.58%) once was among the most prominent companies in the coronavirus vaccine race. The biotech designed its vaccine candidate in only three hours after receiving the coronavirus genetic sequence. And it started a phase 1 trial only a few weeks after one of today's market leaders, Moderna.

Since then, a series of events has pushed Inovio to the back of the pack. The most damaging was the U.S. government's decision to drop funding of its late-stage clinical trial. That was due to the supply of vaccines already on the market. But recently, Inovio announced news that could jump-start its vaccine program. Let's look at the details and find out what this means for the stock.

Two people study a document as they sit in front of a laptop in an office.

Image source: Getty Images.

Inovio's phase 1 trial

First, a bit of background on Inovio's path to this point. Inovio announced positive data from its phase 1 trial shortly after Moderna. Unlike its rival, Inovio didn't go into detail regarding neutralizing antibody levels. And that disappointed investors. Neutralizing antibodies are known to block infection, so they offer solid clues about vaccine performance.

Then, a few months later, the U.S. Food and Drug Administration (FDA) placed a partial clinical hold on Inovio's phase 2/3 trial. The regulatory agency had questions about the trial -- and in particular the device used to deliver the vaccine candidate. Inovio uses its proprietary handheld Cellectra device to introduce product directly into cells through electrical pulses. The FDA lifted the hold on the phase 2 portion of the trial after Inovio provided answers. But the hold on phase 3 remains.

Meanwhile, as mentioned above, the U.S. government decided it wouldn't fund the phase 3 portion of the trial as originally planned. As a result, Inovio changed its strategy to focus on vaccinating parts of the world that lack doses. The company said it would start by conducting late-stage trials outside of the U.S.

So, here's the latest news: Mexico recently authorized Inovio to start a phase 3 trial there. This comes shortly after Brazil and the Philippines agreed to participate in the global trial. Inovio continues to seek permission to add trial sites in other countries.

Vaccination in Africa

This is positive news for Inovio. It means the company can finally proceed with the late-stage testing of its vaccine candidate. And it's true that need remains high in various parts of the world. For example, today on the African continent, only 4.2% of people are fully vaccinated. And Inovio plans to focus on vaccinating Africa, Latin America, and Asia.

Of course, eventually selling vaccine doses to certain low- and middle-income countries won't generate as much revenue as selling doses to the U.S. Still, for a clinical stage company like Inovio, bringing a product to market and generating any level of revenue would be a win.

That said, I would be very hesitant about buying Inovio shares right now. Investors progressively lost confidence in the company following the setbacks I mentioned earlier. The stock soared more than 700% from the start of 2020 through June of that year as Inovio moved from early development through phase 1 trials. Since that time, though, the stock has lost more than 70%.

I think Inovio has to show it can bring a candidate to the regulatory authorization stage before the shares will deliver a sustained gain. As a potential investor, I would want to see positive trial data and Inovio's manufacturing plan. I also would be interested in hearing about advance purchase agreements. Right now, all of that still seems pretty far away.

At the same time, bigger rivals such as Moderna and Pfizer have plenty of time to deliver doses to regions in need -- and that may slowly chip away at Inovio's potential market.

A stock to watch?

Inovio remains a stock to watch. The company's technology is innovative. The vaccine candidate introduces an optimized form of DNA from the coronavirus into cells. The idea is that the cells then produce a protein from the virus -- and the immune system responds.

Inovio is also working on a pan-covid vaccine candidate. This means one that could work against any variant. If Inovio succeeds here, it could be big. But it's much too early to invest in such hopes. The candidate hasn't yet entered clinical trials.

So, yes, Inovio's latest news is positive. And it's reason to keep an eye on what comes next. But until Inovio offers us clear signs it really can bring a product to market, this biotech stock remains high-risk.

Adria Cimino has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals Stock Quote
Inovio Pharmaceuticals
INO
$1.93 (1.58%) $0.03
Pfizer Stock Quote
Pfizer
PFE
$49.49 (-0.16%) $0.08
Moderna Inc. Stock Quote
Moderna Inc.
MRNA
$173.15 (-1.27%) $-2.23

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
351%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.